PLD-104
RET‑mutant NSCLC
PreclinicalActive
Key Facts
About PeLeMed
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
View full company profileRET‑mutant NSCLC
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
View full company profile